ARTICLE | Company News
PureTech Health plc (LSE:PRTC) partnered with Roche (SIX:ROG; OTCQX:RHHBY) to develop PureTech's milk-derived exosome platform to orally deliver Roche's antisense oligonucleotides.
PureTech will receive up to $36 million comprising an upfront payment, early preclinical milestone payments and research support. The company is also eligible to receive over $1 billion in developmental and sales milestones and royalties. Both companies declined to disclose financial details...